Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 9/20 | 0.48 |
| ▸ | CA2 | P00918 | 9/20 | 0.48 |
| ▸ | CA12 | O43570 | 6/20 | 0.48 |
| ▸ | CA9 | Q16790 | 6/20 | 0.48 |
| ▸ | STK17B | O94768 | 1/20 | 0.40 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2855685 | 1.00 | MEN1 (0.62) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL131062 | 1.00 | MEN1 (0.62) | MEN1KMT2AGAATDP1MAOA | |
| Hydrochloric Acid SCHEMBL131061 | 0.98 | MEN1 (0.60) | MEN1KMT2AGAATDP1MAOA | |
| Hydrochloric Acid SCHEMBL21271788 | 0.98 | MEN1 (0.60) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL138402 | 0.95 | MEN1 (0.56) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL2247530 | 0.95 | MEN1 (0.56) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL8171267 | 0.95 | MEN1 (0.56) | MEN1KMT2AGAATDP1MAOA | |
| Hydrochloric Acid SCHEMBL138401 | 0.94 | MEN1 (0.55) | MEN1KMT2AGAATDP1MAOA | |
| Hydrochloric Acid SCHEMBL7352392 | 0.94 | MEN1 (0.55) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL12215023 | 0.94 | TDP1 (0.58) | MEN1KMT2AGAATDP1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988444-B2 | Antimicrobial compounds | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2021-04-27 | — | — | US | disclosed |
| WO-2020191348-A1 | ARGININE GINGIPAIN INHIBITORS | Cortexyme, Inc. (US) | 2020-09-24 | — | — | WO | disclosed |
| US-20190256466-A1 | ANTIMICROBIAL COMPOUNDS | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2019-08-22 | — | — | US | disclosed |
| EP-2812321-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2016-01-06 | — | — | EP | disclosed |
| US-8916702-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-23 | — | — | US | disclosed |
| EP-2812321-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2014-12-17 | — | — | EP | disclosed |
| WO-2013119542-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-15 | — | — | WO | disclosed |
| US-20130203758-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-08 | — | — | US | disclosed |
| US-8362236-B2 | Macrocyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-01-29 | — | — | US | disclosed |
| CN-102443048-A | Synthetic method of 5-membered cyclopeptide | JIANGSU YEW PHARMACEUTICAL CO LTD | 2012-05-09 | — | — | CN | disclosed |
| EP-2119718-B1 | MACROCYCLIC COMPOUND | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2012-04-11 | — | — | EP | disclosed |
| US-7964601-B2 | Agonist or antgonist and binders and inversion of agonist | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20100056510-A1 | Macrocyclic Compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2119718-A1 | MACROCYCLIC COMPOUND | Chugai Seiyaku Kabushiki Kaisha (JP) | 2009-11-18 | — | — | EP | disclosed |
| US-7456184-B2 | Melanocortin receptor-specific compounds | PALATIN TECHNOLOGIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080234289-A1 | Melanocortin Receptor-Specific Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| EP-1885693-A1 | PEPTIDOMIMETICS SELECTIVE FOR THE SOMATOSTATIN RECEPTOR SUBTYPES 1 AND/OR 4 | Wurster, Siegfried (FI) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006123020-A1 | PEPTIDOMIMETICS SELECTIVE FOR THE SOMATOSTATIN RECEPTOR SUBTYPES 1 AND/OR 4 | JUVANTIA PHARMA LTD OY (FI) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056510-A1 | Macrocyclic Compound | HSP90AB1, HSP90B1, HSP90AA1 | MEN1 2984/4885KMT2A 3546/4885GAA 362/4885 |
| US-20190256466-A1 | ANTIMICROBIAL COMPOUNDS | MPO, CFTR, MMP8 | MEN1 3424/4885KMT2A 4809/4885GAA 294/4885 |
| US-20130203758-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, SLC10A1, HCCS | MEN1 4684/4885KMT2A 4752/4885GAA 108/4885 |
| US-20080234289-A1 | Melanocortin Receptor-Specific Compounds | MC1R, MC3R, MC5R | MEN1 330/4885KMT2A 630/4885GAA 4525/4885 |
| US-10988444-B2 | Antimicrobial compounds | MPO, CFTR, MMP8 | MEN1 3424/4885KMT2A 4809/4885GAA 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.